Two biotechnology companies began investor presentations Monday for their upcoming stock market debuts, seeking valuations that could exceed $1 billion as the biotech sector experiences renewed public offering activity.
Kailera Therapeutics, which develops obesity treatments, seeks a market value reaching $1.9 billion, while Alamar Biosciences targets up to $1.1 billion in its public offering.
The biotech industry is returning to public markets following a quiet stretch during much of 2025, helped by recent Federal Reserve interest rate reductions that have encouraged investment in stocks. However, inflation driven by ongoing conflicts could prompt rate increases later this year. The SPDR S&P Biotech ETF has jumped approximately 81% over the past year.
Two additional companies, Seaport Therapeutics and Hemab Therapeutics, also submitted paperwork Friday for U.S. public offerings.
Kailera’s primary drug candidate, ribupatide, competes in the lucrative weight-loss medication market, which analysts project could reach $150 billion in yearly revenue within the next decade. The experimental treatment is undergoing final-phase clinical testing as a weekly injection targeting GLP-1 receptors.
The company plans to sell 33.3 million shares at $14 to $16 each, according to regulatory documents.
Current investors, including Bain Capital Private Equity, Bain Capital Life Sciences and Qatar Investment Authority, have expressed interest in purchasing up to $225 million worth of shares in the offering.
Alamar Biosciences, headquartered in Fremont, California, intends to offer approximately 9.4 million shares priced from $15 to $17 per share.
The protein analysis company creates equipment for identifying trace amounts of protein markers in blood samples, supporting disease research and medical testing.
J.P. Morgan, BofA Securities, and TD Cowen serve as primary investment banks for Alamar’s stock debut.
Kailera has selected Jefferies, J.P. Morgan, Leerink Partners, TD Cowen and Evercore ISI as lead underwriters for its offering.
Kailera plans to trade on the Nasdaq exchange using ticker symbol “KLRA,” while Alamar will use “ALMR.”
